Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort.
Eur Arch Psychiatry Clin Neurosci. 2017-11-10; 268(6): 541-553
DOI: 10.1007/s00406-017-0847-1
Lire sur PubMed
1. Eur Arch Psychiatry Clin Neurosci. 2018 Sep;268(6):541-553. doi:
10.1007/s00406-017-0847-1. Epub 2017 Nov 10.
Relationships between low-grade peripheral inflammation and psychotropic drugs
in schizophrenia: results from the national FACE-SZ cohort.
Fond G(1)(2)(3)(4)(5), Resseguier N(6)(7)(8), Schürhoff F(6)(9)(10)(8), Godin
O(6)(9)(10)(8), Andrianarisoa M(6)(9)(10)(8), Brunel L(6)(9)(10)(8), Bulzacka
E(6)(9)(10)(8), Aouizerate B(6)(11)(12)(8)(13), Berna F(6)(14)(8), Capdevielle
D(6)(15)(8), Chereau I(6)(16)(8), D’Amato T(6)(17)(8), Dubertret C(6)(18)(8),
Dubreucq J(6)(19)(8), Faget C(6)(20)(8), Gabayet F(6)(19)(8), Lançon
C(6)(20)(8), Llorca PM(6)(16)(8), Mallet J(6)(18)(8), Misdrahi
D(6)(11)(12)(8)(21), Passerieux C(6)(22)(8), Rey R(6)(17)(8), Schandrin
A(6)(15)(8), Urbach M(6)(22)(8), Vidailhet P(14)(8), Boyer L(6)(7)(8), Leboyer
M(6)(9)(10)(8); FACE-SZ (FondaMental Academic Centers of Expertise for
Schizophrenia) group.
Collaborators: Andrianarisoa M, Aouizerate B, Berna F, Blanc O, Brunel L,
Bulzacka E, Capdevielle D, Chereau-Boudet I, Chesnoy-Servanin G, Danion JM,
D’Amato T, Deloge A, Delorme C, Denizot H, Dorey JM, Dubertret C, Dubreucq J,
Faget C, Fluttaz C, Fond G, Fonteneau S, Gabayet F, Giraud-Baro E, Hardy-Bayle
MC, Lacelle D, Lançon C, Laouamri H, Leboyer M, Le Gloahec T, Le Strat Y, Llorca
PM, Mallet J, Metairie E, Misdrahi D, Offerlin-Meyer I, Passerieux C, Peri P,
Pires S, Portalier C, Rey R, Roman C, Sebilleau M, Schandrin A, Schürhoff F,
Tessier A, Tronche AM, Urbach M, Vaillant F, Vehier A, Vidailhet P, Vilain J,
Vilà E, Yazbek H, Zinetti-Bertschy A.
Author information:
(1)Fondation FondaMental, Créteil, France. .
(2)INSERM U955, équipe de psychiatrie translationnelle, Créteil, France.
.
(3)Université Paris-Est Créteil, DHU Pe-PSY, Pôle de Psychiatrie des Hôpitaux
Universitaires H Mondor, Créteil, France. .
(4)Bordeaux Sleep Clinique, Pellegrin University Hospital, Bordeaux University,
USR CNRS 3413 SANPSY, Research Unit, 33000, Bordeaux, France.
.
(5)Pole de Psychiatrie, Hôpital A. Chenevier, 40 rue de Mesly, 94010, Créteil,
France. .
(6)Fondation FondaMental, Créteil, France.
(7)Pôle psychiatrie universitaire, CHU Sainte-Marguerite, 13274, Marseille Cedex
09, France.
(8)Bordeaux Sleep Clinique, Pellegrin University Hospital, Bordeaux University,
USR CNRS 3413 SANPSY, Research Unit, 33000, Bordeaux, France.
(9)INSERM U955, équipe de psychiatrie translationnelle, Créteil, France.
(10)Université Paris-Est Créteil, DHU Pe-PSY, Pôle de Psychiatrie des Hôpitaux
Universitaires H Mondor, Créteil, France.
(11)Centre Hospitalier Charles Perrens, 33076, Bordeaux, France.
(12)Université de Bordeaux, 33000, Bordeaux, France.
(13)Inserm, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale,
U862, 33000, Bordeaux, France.
(14)Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, INSERM
U1114, Fédération de Médecine Translationnelle de Strasbourg, 67000, Strasbourg,
France.
(15)Service Universitaire de Psychiatrie Adulte, Hôpital la Colombière, CHRU
Montpellier, Université Montpellier 1, Inserm 1061, Montpellier, France.
(16)CMP B, CHU, EA 7280 Faculté de Médecine, Université d’Auvergne, BP 69,
63003, Clermont-Ferrand Cedex 1, France.
(17)INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences de Lyon,
Université Claude Bernard Lyon 1, Equipe PSYR2, Centre Hospitalier Le Vinatier,
Pole Est, 95 bd Pinel, BP 30039, 69678, Bron Cedex, France.
(18)AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, Inserm
U894, Université Paris Diderot, Sorbonne Paris Cité, Faculté de médecine, 92700,
Colombes, France.
(19)Centre Référent de Réhabilitation Psychosociale, CH Alpes Isère, Grenoble,
France.
(20)Assistance Publique des Hôpitaux de Marseille (AP-HM), pôle universitaire de
psychiatrie, Marseille, France.
(21)CNRS, UMR 5287-INCIA, Bordeaux, France.
(22)Service de psychiatrie d’adulte, Centre Hospitalier de Versailles, UFR des
Sciences de la Santé Simone Veil, Université Versailles Saint-Quentin en
Yvelines, Versailles, France.
Low-grade inflammation has repeatedly been associated with schizophrenia (SZ)
and in particular with cognitive impairment. Female gender, overweight and
tobacco smoking have been suggested as risk factors to increase inflammation
while preclinical inconsistent findings have been found regarding the
association with psychotropic drugs. The aim of this study was to explore if
psychotropic drugs were associated with inflammation in SZ and to determine
which psychotropic drug was associated with inflammation in stable SZ subjects
while considering clinical confounding factors. Participants were consecutively
included in the network of the FondaMental Expert Centers for Schizophrenia and
received a thorough clinical assessment, including recording of current
treatment. High-sensitivity CRP (hs-CRP) was measured for each participant as a
proxy to define peripheral low-grade inflammation. The zero-inflated Poisson
regression model estimated the relationship between low-grade inflammation and
psychotropic drug. Four hundred and five stabilized, community-dwelling SZ
subjects (mean age = 32.6 years, 74% male gender) have been included. In total,
148 participants (36.5%) were found with undetectable blood hs-CRP level. The
probability of having an undetectable CRP was associated with a lower body mass
index (p 0 mg/L). Low-grade inflammation was significantly associated with
female gender (p = 0.004), higher body mass index (p